Phentolamine Ophthalmic Solution 0.75% — Topline data
2026
We are currently enrolling participants in LYNX-3, with results expected in 2026.Source filing
IRD biotech catalysts & pipeline
OPUS GENETICS INC · Data as of 2026-09-08
Upcoming catalysts
OPGx-BEST1 — Topline data
Sep 2026
• Enrollment was completed in Cohort 1 of the Phase 1/2 trial (BIRD-1), with 3-month topline data from Cohort 1 expected during the second week of September 2026, assuming all participants complete their assessments as scheduled.Source filing
Phentolamine Ophthalmic Solution 0.75% (PS) — PDUFA
Oct 17
In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026.Source filing
OPGx-LCA5 — Topline data
Late 2027
Topline data from the study is expected by the end of 2027.Source filing
OPGx-BEST1 — Conference presentation
Oct 1–Oct 4
In addition, we plan to present the data at the annual EURETINA Congress taking place in Vienna, Austria in October 2026.Source filing